Intent-to-randomize corrections for missing data resulting from run-in selection bias in clinical trials for chronic conditions

Journal of Biopharmaceutical Statistics

Volumn 21, Issue 2, 2011, Pages 263-270

  Berger, Vance W ^a   Vali, Behrang ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Enrichment; Intent to Randomize; Missing Completely at Random; Run in

Indexed keywords

ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); MEDICAL AUDIT; MEDICAL DECISION MAKING; METHODOLOGY; MISSING DATA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS;

CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; INTENTION TO TREAT ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79952605381     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2011.550107     Document Type: Article

References (25)

1. Berger, V. W. (2001). The p-value interval as an inferential tool. Statistician 50:79-85. (Pubitemid 33597890)
2. Berger, V. W. (2004a). On the generation and ownership of alpha in medical studies. Controlled Clinical Trials 25:613-619. (Pubitemid 39592865)
3. Berger, V. W. (2004b). Valid adjustment of randomized comparisons for binary covariates. Biometrical Journal 5:589-594. (Pubitemid 39508110)
4. Berger, V. W. (2005). Selection Bias and Covariate Imbalances in Randomized Clinical Trials. Chichester: John Wiley & Sons.
5. Berger, V. W., Rezvani, A., Makarewicz, V. A. (2003). Direct effect on validity of response run-in selection in clinical trials. Controlled Clinical Trials 24:156-166. (Pubitemid 36412015)
6. Blackwelder, W. C., Hastings, B. K., Lee, M. L. F., Deloria, M. A. (1990). Value of a run-in period in a drug trial during pregnancy. Controlled Clinical Trials 11:187-198. (Pubitemid 20204762)
7. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K., Schnitzer, T. J. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New England Journal of Medicine 343:1520-1528.
8. Brittain, E., Wittes, J. (1990). The run-in period in clinical trials. The effect of misclassification on efficiency. Controlled Clinical Trials 11:327-338.
9. CAST Investigators. (1989). Preliminary report, Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New England Journal of Medicine 321:406-412.
10. Greenhouse, J. B., Meyer, M. M. (1991). A note on randomization and selection bias in maintenance therapy clinical trials. Psychopharmacology Bulletin 27:225-229.
11. Greenhouse, J. B., Stangl, D., Kupfer, D., Prien, R. (1991). Methodologic issues in maintenance therapy clinical trials. Archives of General Psychiatry 48:313-318.
12. Hopkins, J. (2005). Journal criticizes Vioxx study for omitting three heart attacks. British Medical Journal 331:1423.
13. Knipschild, P., Leffers, P., Feinstein, A. R. (1991). The qualification period. Journal of Clinical Epidemiology 6:461-464.
14. Lachin, J. M. (1999). Worst-rank score analysis with informatively missing observations in clinical trials. Controlled Clinical Trials 20:408-422. (Pubitemid 29460918)
15. Lang, J. M. (1987). The effect of a run-in on the generalizability of the results of the Physicians-Health-Study. American Journal of Epidemiology 126:777.
16. Lang, J. M., Buring, J. E., Rosner, B., Cook, N., Hennekens, C. H. (1991). Estimating the effect of the run-in on the power of the Physicians Health Study. Statistics in Medicine 10:1585-1593.
17. Leber, P. D., Davis, C. S. (1998). Threats to the validity of clinical trials employing enrichment strategies for sample selection. Controlled Clinical Trials 19:178-187. (Pubitemid 28191972)
18. Little, R. J. A., Rubin, D. B. (1987). Statistical Analysis with Missing Data. New York: John Wiley & Sons.
19. Pablos-Mendez, A., Graham, B., Shea, S. (1998). Run-in periods in randomized trials, Implications for the application of results in clinical practice. Journal of the American Medical Association 279:222-225. (Pubitemid 28133785)
20. Prytowsky, E. N., Katz, A., Knilans, T. K. (1990). Ventricular arrhythmias, risk stratification and approach to therapy after cardiac arrhythmia suppression trial (CAST). Pace 13:1480-1487. (Pubitemid 20383419)
21. Reimherr, F., Ward, M., Byerley, W. (1989). The introductory placebo washout, a retrospective evaluation. Psychiatry Research 30:191-199. (Pubitemid 20005930)
22. Senn, S. (1997). Statistical Issues in Drug Development. Chichester: John Wiley & Sons.
23. Temple, R. J. (1994). Special study designs-early escape, enrichment, studies in nonresponders. Communication in Statistics-Theory and Methods 23:499-531.
24. Temple, R. J. (2005). enrichment designs, efficiency in development of cancer treatments. Journal of Clinical Oncology 23:4838-4839. (Pubitemid 46223984)
25. Unnebrink, K., Windeler, J. (2001). Intent-to-treat, methods for dealing with missing values in clinical trials of progressively deteriorating disease. Statistics in Medicine 20:3931-3946.